PCT’s analytical development team works with clients to create testing methods that satisfy the Chemistry Manufacturing and Controls (CMC) requirements of an IND or BLA filing with the FDA. PCT develops analytical methods used for testing cell therapy products for identity, purity, potency and sterility, and also for certain additional measures of safety, as required by the FDA. PCT also performs assay validation services.
Examples of analytical methods PCT can help clients develop include:
David O’Neill, MD, Director, Analytical Development & Medical Director
MD Ohio State University
David is licensed to practice medicine in CA, NJ and NY, and is board-certified in anatomic pathology, clinical pathology and blood banking/transfusion medicine. He has over 20 years of academic and 5 years of industry research experience in hematology, immunology and stem cell biology, including the molecular biology and biochemistry of globin gene regulation, GMP production of cellular immunotherapies, vaccine design and immune monitoring for clinical immunotherapy trials for cancer, autoimmune disease and HIV infection.
In addition to analytical development, we also offer process development services. CLICK HERE to learn more.
Together, PCT’s process and analytical development services, combined with our Center for Innovation & Engineering, ensure that our cell therapy clients will have a manufacturing process that is optimized to deliver products in a reasonable timeframe, in a scalable, sustainable way that meets all applicable regulatory requirements.